Prana Biotechnology has provided an update on its clinical development program for Alzheimer's disease. In Professor Colin Masters' July presentation, which includes data from Prana's phase 2 IMAGINE and EURO trials, he noted that the starting amyloid burden level in the PBT2 treated participant group had an important bearing on the decrease of amyloid over time in that participant, whereas there was no such correlation in the placebo group. Separately, Prana has confirmed the top line finding that there is a very promising trend towards the preservation of brain volume in PBT2 treated patients compared to placebo patients.
- Health Care Industry
- Pharmaceuticals & Drug Trials